On September 4, Moderna, Inc. rose 3.55% in pre-market trading, trading at 153.82 USD/share, with Turnover of 18.54 million USD.
Within the Biotechnology sector where Moderna, Inc. belongs, among individual stocks, Amgen down 0.54%, AbbVie down 0.08%, Gilead Sciences down 0.05%, Alnylam Pharmaceuticals up 0.19%, Hyperliquid Strategies Inc down 0.39%.
Moderna, Inc. is a leader in messenger RNA (mRNA) medicine. Its mRNA platform has enabled the development of therapeutics and vaccines across infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. The company has strategic collaborations with Merck, AstraZeneca, Vertex Pharmaceuticals, and others.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments